About

Interior of a relatively full Indonesian subway or train car.

The Adjuvant Investment Strategy

Adjuvant’s strategy aims to drive meaningful improvements in the public health of low- and middle-income countries while pursuing top-tier financial returns. Adjuvant’s focus areas include:

Neglected, high-burden, and emerging infectious diseases, including antimicrobial resistance and pandemic threats
Maternal, newborn, and child health challenges
Reproductive and sexual health
Nutrition

Adjuvant directs the majority of its investment activity to opportunities that have human efficacy signals from a phase II-or-later clinical trial or similar arm’s-length evaluations. We look for compelling proof-of-concept data to support our investment decisions.

A Commitment to Meaningful, Measurable Public Health Impact and SDG 3

As a signatory of the Operating Principles for Impact Management (the Impact Principles), Adjuvant Capital engaged BlueMark to undertake an independent verification of the alignment of Adjuvant Capital’s impact management system with the Impact Principles. Adjuvant Capital’s assets under management covered by the Impact Principles totals $300 million USD, for the period ending September 30, 2023. Our detailed BlueMark verification report can be found here.

Adjuvant’s ESG Policy can be found here.

Assets under management figure as reflected in Adjuvant Capital’s Disclosure Statement as of September 30, 2023. BlueMark’s assessment did not include verification of the AUM figure.

Grievance Mechanism

Adjuvant Capital, L.P. (“Adjuvant”) maintains a grievance mechanism in line with IFC Performance Standard 1 and the UN Guiding Principles on Business and Human Rights. It is open to the general public and, in particular, to people affected by the investments of our funds and to workers and communities affected by the operations of our portfolio companies. It may be used, at no cost, to raise any concern, comment, or grievance about the environmental or social performance of our funds or their portfolio companies.

How to raise a concern.

Concerns may be raised in any language, in writing or verbally: by email to grievances@adjuvantcapital.com; through the contact form on this website; or by post to Adjuvant Capital, L.P., 500 5th Avenue, Suite 4000, New York, NY 10110, USA, marked for the attention of the E&S Manager. Concerns may be raised anonymously. Where contact details are provided, they are treated confidentially and used only to process the grievance. Adjuvant does not tolerate retaliation of any kind against anyone who raises a concern in good faith.

How concerns are handled.

Every grievance is registered and logged, whether received in writing or verbally. We acknowledge receipt within ten business days and assess and investigate each grievance in a manner proportionate to its nature and severity, engaging the relevant portfolio company and qualified external experts where appropriate. Where the complainant has provided contact details, we communicate the outcome and the measures taken to resolve, or facilitate the resolution of, the concern. A summary of grievances received and their resolution is reported annually to the advisory committees of our funds.

Investment Opportunities Hiding in Plain Sight

Adjuvant seeks out public health challenges where the burden is highest and the need is greatest

Post-Partum Hemorrhage (PPH)

Post-partum bleeding is a life-threatening condition that does not discriminate on the basis of geography or socio-economic status--mothers in every country are at risk, and PPH is one of the most common and most deadly complications of childbirth. New, improved, and more widely-available interventions would prevent millions of children from losing their mother after birth.

Pandemic Threats

As H1N1, MERS, and COVID-19 have shown us, the global population is at constant risk of a pandemic from an emerging pathogen. Investing in new tools for surveillance and rapid response technologies has the potential to pay enormous public health and economic dividends in the future.

Anti-Microbial Resistance

Increasing prevalence of treatment-resistant bacteria is emerging as one of the most concerning public health threats in developed and developing countries alike. New diagnostics to identify the appropriate treatment for these pathogens and novel therapies will be essential to combat drug-resistant "superbugs" in the future.

Mosquito-Borne Diseases

The humble mosquito may be mankind's greatest enemy, responsible for hundreds of thousands of deaths and millions of illnesses each year thanks to the viruses and parasites that can be transmitted with their bites. Vector-control tools, vaccines, and new treatments are all needed to combat the public health threat posed by these tiny insects.

Soil-Transmitted Helminths

As many as a billion people are at perpetual risk of recurrent infection from soil-transmitted helminths such as hookworm, whipworm, and roundworm. New tools to screen, treat, and/or vaccinate against these infections would benefit hundreds of millions around the world--predominantly children.